O	0	3	The
B-intervention	4	12	Prosigna
I-intervention	13	17	gene
I-intervention	18	28	expression
I-intervention	29	34	assay
O	35	38	and
O	39	53	responsiveness
O	54	56	to
O	57	65	adjuvant
O	66	82	cyclophosphamide
O	82	83	-
O	83	88	based
O	89	101	chemotherapy
O	102	104	in
B-eligibility	105	118	premenopausal
I-eligibility	119	123	high
I-eligibility	123	124	-
I-eligibility	124	128	risk
I-eligibility	129	137	patients
I-eligibility	138	142	with
I-eligibility	143	149	breast
I-eligibility	150	156	cancer
O	156	157	.

O	158	161	The
O	162	167	PAM50
O	167	168	-
O	168	173	based
O	174	175	(
O	175	183	Prosigna
O	183	184	)
O	185	189	risk
O	190	192	of
O	193	203	recurrence
O	204	205	(
O	205	208	ROR
O	208	209	)
O	210	215	score
O	216	219	and
O	220	229	intrinsic
O	230	238	subtypes
O	239	242	are
O	243	253	prognostic
O	254	257	for
O	258	263	women
O	264	268	with
O	269	273	high
O	273	274	-
O	274	278	risk
O	279	285	breast
O	286	292	cancer
O	292	293	.

O	294	296	We
O	297	308	investigate
O	309	312	the
O	313	323	predictive
O	324	331	ability
O	332	334	of
O	335	343	Prosigna
O	344	353	regarding
O	354	357	the
O	358	371	effectiveness
O	372	374	of
O	375	391	cyclophosphamide
O	391	392	-
O	392	397	based
O	398	406	adjuvant
O	407	419	chemotherapy
O	420	422	in
O	423	436	premenopausal
O	437	445	patients
O	446	450	with
O	451	455	high
O	455	456	-
O	456	460	risk
O	461	467	breast
O	468	474	cancer
O	474	475	.

O	476	484	Prosigna
O	485	491	assays
O	492	496	were
O	497	506	performed
O	507	509	on
O	510	513	the
O	514	524	NanoString
O	525	533	platform
O	534	536	in
O	537	543	tumors
O	544	548	from
O	549	561	participants
O	562	564	in
B-ethinicity	565	571	Danish
O	572	578	Breast
O	579	585	Cancer
O	586	591	Group
O	592	593	(
O	593	597	DBCG
O	597	598	)
O	599	602	77B
O	602	603	,
O	604	605	a
O	606	610	four
O	610	611	-
O	611	614	arm
O	615	620	trial
O	621	625	that
O	626	636	randomized
B-eligibility	637	650	premenopausal
I-eligibility	651	656	women
I-eligibility	657	661	with
I-eligibility	662	666	high
I-eligibility	666	667	-
I-eligibility	667	671	risk
I-eligibility	672	677	early
I-eligibility	678	684	breast
I-eligibility	685	691	cancer
O	692	694	to
B-control	695	697	no
I-control	698	706	systemic
I-control	707	716	treatment
I-control	716	717	,
O	718	728	levamisole
O	728	729	,
O	730	734	oral
O	735	751	cyclophosphamide
O	752	753	(
O	753	754	C
O	754	755	)
O	756	758	or
O	759	775	cyclophosphamide
O	775	776	,
O	777	789	methotrexate
O	790	793	and
O	794	806	fluorouracil
O	807	808	(
O	808	811	CMF
O	811	812	)
O	812	813	.

O	814	816	In
O	817	822	total
O	822	823	,
O	824	828	this
O	829	842	retrospective
O	843	851	analysis
O	852	860	included
B-total-participants	861	864	460
O	865	870	women
O	871	872	(
O	872	874	40
O	874	875	%
O	876	878	of
O	879	882	the
O	883	887	1146
O	888	898	randomized
O	899	907	patients
O	907	908	)
O	908	909	.

O	910	913	The
O	914	924	continuous
O	925	933	Prosigna
O	934	937	ROR
O	938	943	score
O	944	947	was
O	948	958	prognostic
O	959	961	in
O	962	965	the
O	966	968	no
O	969	977	systemic
O	978	987	treatment
O	988	993	group
O	994	995	(
O	995	1005	unadjusted
O	1006	1007	P
O	1008	1009	<
O	1010	1011	0
O	1011	1012	.
O	1012	1015	001
O	1016	1019	for
B-outcome	1020	1027	disease
I-outcome	1027	1028	-
I-outcome	1028	1032	free
I-outcome	1033	1041	survival
I-outcome	1042	1043	(
I-outcome	1043	1046	DFS
I-outcome	1046	1047	)
O	1047	1048	,
O	1049	1050	P
O	1051	1052	=
O	1053	1054	0
O	1054	1055	.
O	1055	1058	001
O	1059	1062	for
B-outcome	1063	1070	overall
I-outcome	1071	1079	survival
I-outcome	1080	1081	(
I-outcome	1081	1083	OS
I-outcome	1083	1084	)
O	1084	1085	)
O	1085	1086	.

O	1087	1089	No
O	1090	1103	statistically
O	1104	1115	significant
O	1116	1127	interaction
O	1128	1130	of
O	1131	1141	continuous
O	1142	1145	ROR
O	1146	1151	score
O	1152	1155	and
O	1156	1165	treatment
O	1166	1168	on
B-outcome	1169	1172	DFS
I-outcome	1173	1176	and
I-outcome	1177	1179	OS
O	1180	1183	was
O	1184	1189	found
O	1189	1190	.

O	1191	1192	A
O	1193	1199	highly
O	1200	1211	significant
O	1212	1223	association
O	1224	1227	was
O	1228	1236	observed
O	1237	1244	between
O	1245	1254	intrinsic
O	1255	1263	subtypes
O	1264	1267	and
O	1268	1269	C
O	1269	1270	/
O	1270	1273	CMF
O	1274	1283	treatment
O	1284	1287	for
O	1288	1291	DFS
O	1292	1293	(
O	1293	1305	Pinteraction
O	1306	1307	=
O	1308	1309	0
O	1309	1310	.
O	1310	1313	003
O	1314	1324	unadjusted
O	1324	1325	,
O	1326	1327	P
O	1328	1329	=
O	1330	1331	0
O	1331	1332	.
O	1332	1335	001
O	1336	1344	adjusted
O	1344	1345	)
O	1346	1349	and
O	1350	1352	OS
O	1353	1354	(
O	1354	1366	Pinteraction
O	1367	1368	=
O	1369	1370	0
O	1370	1371	.
O	1371	1373	04
O	1373	1374	)
O	1374	1375	.

O	1376	1378	In
O	1379	1382	the
O	1383	1391	adjusted
O	1392	1400	analysis
O	1401	1410	treatment
O	1411	1415	with
O	1416	1417	C
O	1417	1418	/
O	1418	1421	CMF
O	1422	1425	was
O	1426	1436	associated
O	1437	1441	with
O	1442	1443	a
O	1444	1451	reduced
O	1452	1456	risk
O	1457	1459	of
B-outcome	1460	1463	DFS
I-outcome	1464	1470	events
O	1471	1473	in
O	1474	1482	patients
O	1483	1487	with
B-outcome	1488	1493	basal
I-outcome	1493	1494	-
I-outcome	1494	1498	like
O	1499	1500	(
O	1500	1506	hazard
O	1507	1512	ratio
O	1513	1514	(
O	1514	1516	HR
O	1516	1517	)
O	1518	1519	0
O	1519	1520	.
O	1520	1522	14
O	1522	1523	;
O	1524	1526	95
O	1526	1527	%
O	1528	1530	CI
O	1531	1532	0
O	1532	1533	.
O	1533	1535	06
O	1535	1536	;
O	1537	1538	0
O	1538	1539	.
O	1539	1541	32
O	1541	1542	)
O	1543	1546	and
B-outcome	1547	1554	luminal
I-outcome	1555	1556	B
O	1557	1558	(
O	1558	1560	HR
O	1561	1562	0
O	1562	1563	.
O	1563	1565	48
O	1565	1566	;
O	1567	1569	95
O	1569	1570	%
O	1571	1573	CI
O	1574	1575	0
O	1575	1576	.
O	1576	1578	27
O	1578	1579	;
O	1580	1581	0
O	1581	1582	.
O	1582	1584	84
O	1584	1585	)
O	1586	1594	subtypes
O	1595	1598	but
O	1599	1602	not
O	1603	1605	in
O	1606	1614	patients
O	1615	1619	with
B-outcome	1620	1625	Human
I-outcome	1626	1635	epidermal
I-outcome	1636	1642	growth
I-outcome	1643	1649	factor
I-outcome	1650	1658	receptor
I-outcome	1658	1659	-
I-outcome	1659	1667	enriched
O	1668	1669	(
O	1669	1671	HR
O	1672	1673	1
O	1673	1674	.
O	1674	1676	05
O	1676	1677	;
O	1678	1680	95
O	1680	1681	%
O	1682	1684	CI
O	1685	1686	0
O	1686	1687	.
O	1687	1689	56
O	1689	1690	;
O	1691	1692	1
O	1692	1693	.
O	1693	1695	95
O	1695	1696	)
O	1697	1699	or
B-outcome	1700	1707	luminal
I-outcome	1708	1709	A
O	1710	1711	(
O	1711	1713	HR
O	1714	1715	0
O	1715	1716	.
O	1716	1718	61
O	1718	1719	;
O	1720	1722	95
O	1722	1723	%
O	1724	1726	CI
O	1727	1728	0
O	1728	1729	.
O	1729	1731	32
O	1731	1732	;
O	1733	1734	1
O	1734	1735	.
O	1735	1737	16
O	1737	1738	)
O	1739	1747	subtypes
O	1747	1748	.

O	1749	1752	The
O	1753	1761	Prosigna
O	1762	1765	ROR
O	1766	1771	score
O	1772	1775	and
O	1776	1785	intrinsic
O	1786	1794	subtypes
O	1795	1799	were
O	1800	1810	prognostic
O	1811	1813	in
O	1814	1818	high
O	1818	1819	-
O	1819	1823	risk
O	1824	1837	premenopausal
O	1838	1846	patients
O	1847	1851	with
O	1852	1858	breast
O	1859	1865	cancer
O	1865	1866	,
O	1867	1870	and
O	1871	1880	intrinsic
O	1881	1889	subtypes
O	1890	1898	identify
O	1899	1903	high
O	1903	1904	-
O	1904	1908	risk
O	1909	1917	patients
O	1918	1922	with
O	1923	1925	or
O	1926	1933	without
O	1934	1939	major
O	1940	1947	benefit
O	1948	1952	from
O	1953	1961	adjuvant
O	1962	1963	C
O	1963	1964	/
O	1964	1967	CMF
O	1968	1977	treatment
O	1977	1978	.
